Figure S1. Forest plot for overall response rate of topotecan vs. other agents. M-H, Mantel Haenszel; df, degree of freedom; 95% CI, 95% confidence interval.

	Experimental		Control			Risk ratio		Risk ratio		
Study or subgroup	Events	Total	Events	Total	Weight	M-H, random, 95% CI		M-H, rand	lom, 95% CI	
Baize 2020	39	81	19	81	17.3%	2.05 [1.30, 3.23]				
Chiappori 2016	0	29	2	15	2.3%	0.11 [0.01, 2.09]		_	 	
Evans 2015	0	73	8	79	2.5%	0.06 [0.00, 1.08]		•	+	
Goto 2016	61	83	23	86	18.3%	2.75 [1.89, 3.99]			-	
Inoue 2008	11	29	4	30	10.6%	2.84 [1.02, 7.92]			-	
Jotte 2011	22	50	4	26	11.3%	2.86 [1.10, 7.43]			-	
O'Brien 2006	0	70	5	71	2.4%	0.09 [0.01, 1.64]	<u> </u>		_	
von Pawel 1999	19	104	26	107	16.5%	0.75 [0.44, 1.27]		-	+	
von Pawel 2014	132	424	36	213	18.7%	1.84 [1.32, 2.56]			-	
Total (95% CI)		943		708	100.0%	1.53 [0.95, 2.48]			•	
Total events	284		127							
Heterogeneity: Tau^2 =0.29; Chi^2 =31.33, df =8 (P=0.0001); I^2 =74% Test for overall effect: Z=1.75 (P=0.08)							0.005	0.1	1 10	200
							Favours TC	POTECAN	Favours other agents	

Figure S2. Forest plot for G3-4 anemia rate of topotecan vs. other agents. M-H, Mantel Haenszel; df, degree of freedom; 95% CI, 95% confidence interval.

Study or subgroup	Experim Events	nental Total	Cont Events	rol Total	Weight	Risk ratio M-H, random, 95% CI		Risk ratio M-H, random, 95% CI				
						, ,		-	1			
Baize 2020	11	81	20	81	13.1%	0.55 [0.28, 1.07]		3.35				
Chiappori 2016	1	29	1	15	4.8%	0.52 [0.03, 7.70]		25 page 1752	- A			
Evans 2015	3	89	23	88	10.6%	0.13 [0.04, 0.41]						
Goto 2016	76	90	25	90	14.2%	3.04 [2.15, 4.29]			-			
Inoue 2008	6	29	9	30	12.0%	0.69 [0.28, 1.69]		-	 			
Jotte 2011	12	49	7	23	12.5%	0.80 [0.37, 1.77]		_	+			
O'Brien 2006	0	70	18	71	4.6%	0.03 [0.00, 0.45]	(C)	•				
von Pawel 1999	20	104	44	107	13.9%	0.47 [0.30, 0.74]		-				
von Pawel 2014	65	408	60	197	14.3%	0.52 [0.38, 0.71]		-				
Total (95% CI)		949		702	100.0%	0.55 [0.27, 1.12]		•	-			
Total events	194		207									
Heterogeneity: Tau ²	-0 03· Ch	ni ² _88 7	76 df-8 (E	2~0 000	01). 12-01%	<u>,</u>	+	-	+ + +			
				\0.000	01),1 = 91 /	5	0.002	0.1	1 10	500		
Test for overall effect: Z=1.64 (P=0.10)							Favours	other agents	Favours TOPOTI	ECAN		

Figure S3. Forest plot for febrile neutropenia rate of topotecan vs. other agents. M-H, Mantel Haenszel; df, degree of freedom; 95% CI, 95% confidence interval.

Study or subgroup	Experimental Control						Risk ratio M-H, random, 95% CI				
Study or subgroup	Events	Total	Events	Total	Weight	M-H, random, 95% CI		M-H, rando	m, 95% CI		
Baize 2020	5	81	9	81	16.5%	0.56 [0.19,1.59]		-	+		
Chiappori 2016	0	0	0	0		Not estimable					
Evans 2015	16	89	20	88	20.7%	0.79 [0.44,1.42]		-	+		
Goto 2016	26	90	6	90	18.5%	4.33 [1.87,10.02]			-		
Inoue 2008	4	29	1	30	8.6%	4.14 [0.49,34.86]		20 7	•		
Jotte 2011	5	49	2	23	12.1%	1.17 [0.25,5.60]			•		
O'Brien 2006	0	70	2	71	5.2%	0.20 [0.01,4.15]		-			
von Pawel 1999	0	0	0	0		Not estimable			0.00		
von Pawel 2014	41	408	6	197	18.4%	3.30 [1.42,7.64]			-		
Total (95% CI)		816		580	100.0%	1.50 [0.68,3.28]			•		
Total events	97		46								
Heterogeneity: Tau ² =0.68; Chi ² =20.60, df=6 (P=0.002); l ² =71%							0.001	0.1	1 10	1000	
Test for overall effect	π: Z=1.01	(P=0.31	1)					irs other agents	Favours TOPOTE		

Figure S4. Forest plot for G3-4 neutropenia rate of topotecan vs. other agents. M-H, Mantel Haenszel; df, degree of freedom; 95% CI, 95% confidence interval.

	Experimental Control		trol		Risk ratio				
Study or subgroup	Events	Total	Events	Total	Weight	M-H, random, 95% CI	M-H,	random, 95% CI	
Baize 2020	11	81	18	81	6.5%	0.61 [0.31,1.21]	-	•	
Chiappori 2016	0	29	4	15	0.6%	0.06 [0.00,1.03]	700		
Evans 2015	50	89	69	88	14.9%	0.72 [0.58,0.89]		-	
Goto 2016	75	90	77	90	16.4%	0.97 [0.86,1.10]		•	
Inoue 2008	28	29	26	30	15.9%	1.11 [0.95,1.30]		+	
Jotte 2011	30	49	18	23	12.9%	0.78 [0.57,1.07]		-	
O'Brien 2006	0	70	43	71	0.6%	0.01 [0.00,0.19]			
von Pawel 1999	86	104	92	107	16.5%	0.96 [0.86,1.08]		*	
von Pawel 2014	169	408	106	197	15.6%	0.77 [0.65,0.92]		•	
Total (95% CI)		949		702	100.0%	0.83 [0.66,1.03]		•	
Total events	449		453						
Heterogeneity: Tau ² =0.07;Chi ² =62.88, df=8 (P<0.00001); l ² =87% Test for overall effect: Z=1.70 (P=0.09)							0.001 0.1	1 10	1000
	,				Favours other agents	Favours TOPC	DTECAN		

Figure S5. Forest plot for G3-4 thrombocytopenia rate of topotecan vs. other agents. M-H, Mantel Haenszel; df, degree of freedom; 95% CI, 95% confidence interval.

Study or subgroup	Experii Events	mental Total	Con Events	trol Total	Weight	Risk ratio M-H, random, 95% CI		Ris M-H, rand	k ratio lom, 9		
Baize 2020	25	81	29	81	13.7%	0.86 [0.56, 1.33]		_	•		20
Chiappori 2016	2	29	4	15	6.5%	0.26 [0.05, 1.25]		-	+		
Evans 2015	4	89	40	88	9.9%	0.10 [0.04, 0.26]		-			
Goto 2016	37	90	25	90	13.8%	1.48 [0.98, 2.24]			-		
Inoue 2008	8	29	12	30	11.7%	0.69 [0.33, 1.44]		-	+		
Jotte 2011	19	49	14	23	13.4%	0.64 [0.39, 1.03]		-	-		
O'Brien 2006	0	70	27	71	2.9%	0.02 [0.00, 0.30]	20	100			
von Pawel 1999	15	104	60	107	13.3%	0.26 [0.16, 0.42]		-			
von Pawel 2014	86	408	107	197	14.7%	0.39 [0.31, 0.49]		-			
Total (95% CI)		949		702	100.0%	0.44 [0.26, 0.74]		•			
Total events	196		318								
Heterogeneity: Tau ² =0.48; Chi ² =65.43, df=8 (P<0.00001); I ² =88%							<u> </u>		+	1	
Test for overall effect: Z=3.05 (P=0.002)							0.001	0.1	1	10	1000
							Favours	other agents	Favo	urs TOPOTECAN	